A Phase 1b Study Of PF-04449913 In Combination With Dasatinib or Bosutinib In Chronic Myeloid Leukemia (CML)

Trial Profile

A Phase 1b Study Of PF-04449913 In Combination With Dasatinib or Bosutinib In Chronic Myeloid Leukemia (CML)

Planning
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2011

At a glance

  • Drugs Glasdegib (Primary) ; Bosutinib; Dasatinib
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top